Roche to read out even more data on megablockbuster Ocrevus in MS
It’s been three years since Roche hit the market with its megablockbuster MS drug Ocrevus — but the Swiss pharma isn’t done building on the program that CEO Severin Schwan has called the most successful launch in the company’s 124-year history.
Roche says it’s going to MSVirtual2020 next weekend with new efficacy data for the treatment of multiple sclerosis (MS) and neuromyelitis optica spectrum disorder (NMOSD) patients. Plus, it’s initiating a Phase IIIb study to evaluate Ocrevus at a higher dose for relapsing and primary progressive MS patients, and a Phase IV CHIMES study which will focus on the drug’s efficacy in African American, Hispanic and Latinx American patients.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
